GlassScriptPhysician profile
Pedro J Flores
NPI 1619168218
$1,592.15
in general payments reported to CMS, 2019-2025
14 companies · $91.28 in 2025
The $91.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $507 · 2021: $44.16 · 2022: $98.60 · 2023: $171 · 2024: $174 · 2025: $91.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.26 | 2019-2025 | Farxiga, Fasenra |
| Lilly USA, LLC | $247.14 | 2019-2023 | Emgality, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $168.47 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $146.51 | 2021-2024 | |
| Amarin Pharma, INC. | $142.82 | 2019-2020 | |
| Novo Nordisk INC | $74.41 | 2019-2025 | Wegovy |
| Dexcom, INC. | $65.63 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $44.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.73 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $21.67 | 2023 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $21.04 | 2024 | |
| Exact Sciences Corporation | $19.68 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $17.99 | 2024 | Injectafer |
| Roche Diagnostics Corporation | $14.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.